Spots Global Cancer Trial Database for hematopoietic
Every month we try and update this database with for hematopoietic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | NCT02139280 | Hematologic Mal... | Cyclophosphamid... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | NCT02139280 | Hematologic Mal... | Cyclophosphamid... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS | NCT02204020 | Acute Myeloid L... Myelodysplastic... | 5-azacytidine (... | 18 Years - | University of Pittsburgh | |
| Erlotinib Study for Myelodysplastic Syndrome (MDS) | NCT00977548 | Myelodysplastic... | Erlotinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | NCT03609840 | Hematologic Mal... Nonmalignant Di... Immune Deficien... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Thiotepa | - 17 Years | University of California, San Francisco | |
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | NCT02139280 | Hematologic Mal... | Cyclophosphamid... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | NCT03609840 | Hematologic Mal... Nonmalignant Di... Immune Deficien... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Thiotepa | - 17 Years | University of California, San Francisco | |
| Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | NCT03016130 | Leukemia Myelodysplastic... | Diet | 18 Years - | University of Florida | |
| Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation | NCT01596699 | Myeloid Maligna... Bone Marrow Fai... Transfusion-dep... Congenital Immu... Metabolic Disea... Severe Immune D... | Alemtuzumab Busulfan Fludarabine Clofarabine | 3 Months - 30 Years | University of California, San Francisco | |
| Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms | NCT00665002 | Leukemia | WT-1 Montanide Sargramostim (G... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | NCT00831766 | Myelodysplastic... Acute Myeloid L... | Idarubicin Cytarabine Lenalidomide (R... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | NCT03016130 | Leukemia Myelodysplastic... | Diet | 18 Years - | University of Florida |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
